...for new and generic drugs are demonstrating the progress and the remaining challenges in building a stronger QbD foundation for the CMC review process. With one application cleared and several more under review in the NDA pilot, experience is now growing on how to shape a QbD-based filing from which more regulatory flexibility can flow. How detailed the QbD information should be and how to design a regulatory agreement that will clarify the ongoing commitments are among the issues generating discussion as the NDA pilot proceeds. The Office of Generic Drugs is also digesting the initial positive experience with its question-based review initiative integrating QbD principles into the ANDA review process. [An update on the NDA CMC pilot program by Office of New Drug Quality Assessment official Chi-wan Chen at the DIA annual meeting in late June and summaries by industry participants of their firms’ experience with the NDA and ANDA initiatives are included.]
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.
The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.